For Investors

Exstent has developed a personalised aortic support device that preserves the natural anatomy of the aorta while reducing surgical risk. Our clinically proven technology is now positioned for global expansion through strategic partnerships, manufacturing growth, and regulatory advancement.

Why Invest in Exstent

Proven technology. Established results. Expanding opportunity.

0 +

Patients since 2002

0 +

Cardiac centres using the ExoVasc^® implant worldwide for external aortic support and during the Ross procedure

0 +

Years of clinical data

0 +

Years long-term aortic stability and low reintervention rates

Exstent is building on this success to scale production, enter new markets, and extend access to personalised aortic support, using ExoVasc^® worldwide.

Expanding global reach

This technology is used in over 40 leading cardiac centres across the UK, Europe, Australia and beyond. Each centre operates as part of a growing network of skilled surgeons trained in the use of ExoVasc^®, helping to establish consistent outcomes and best practice worldwide.

Regulatory progress

ExoVasc^® is approved for sale in the UK, EU, AUS, New Zealand, Singapore. As a custom-made device, Exstent’s Quality Management System has been audited and meets the requirements of the EU MDR 2017/745 Conformity Assessment for custom-made class III implantable devices and ISO 13485:2016 for the design, development, manufacture and distribution of custom-made implantable medical devices used to provide external support to the major vessels in the cardiovascular system. Exstent continues to pursue expanded regulatory clearance in new territories while maintaining the highest standards of safety, quality, and compliance across all manufacturing and clinical operations.

A growing global need

Aortic aneurysm and dissection remain major causes of cardiovascular mortality, with few options that preserve the native aorta and valve. ExoVasc^® is part of the continuing shift toward personalised approaches in aortic care, aligning Exstent with a market that values tailored solutions and earlier identification of patients who may benefit from support.

Innovation led by experience

Exstent was founded by engineer and patient Tal Golesworthy, whose personal experience with Marfan syndrome inspired the creation of ExoVasc^®. Today, the leadership team continues to combine engineering, clinical, and commercial expertise to advance the company’s mission and global growth strategy.

Building the future of aortic care together

Exstent welcomes collaboration with surgical centres, distributors, and healthcare investors who share our vision for expanding access to personalised aortic support.

Our partnership opportunities include: